Amylyx Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
AMLX$30.21+2.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Net loss | $(144,735) | $(301,743) |
| Other comprehensive income (loss): | ||
| Foreign currency translation gain (loss) | 627 | (396) |
| Net unrealized (loss) gain on marketable securities | (131) | 107 |
| Other comprehensive income (loss) | 496 | (289) |
| Comprehensive loss | $(144,239) | $(302,032) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.